-+ 0.00%
-+ 0.00%
-+ 0.00%

CytoMed Expands Clinical-Scale NK Cells From Decade-Old Cord Blood; Forms New Cord Blood-Derived Biotech Under LongevityBank To Drive Growth And Revenue

Benzinga·08/28/2025 13:07:25
Listen to the news

CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, is pleased to announce it has successfully expanded clinical-scale natural killer ("NK") cells from cord blood units that have been cryopreserved for more than a decade. This sets the impetus for establishing a new business platform to generate additional revenue streams and future growth.

In light of this recent development, we are re-organizing and streamlining our group structure to create a new cord blood-derived biotech under LongevityBank Pte Ltd ("LongevityBank", previously known as IPSCBank Pte Ltd incorporated in 2019) which owns 100% of our licensed cord blood bank, IPSC Depository Sdn Bhd ("IPSC Depository").